Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.6060
-0.0309 (-4.85%)
Apr 29, 2025, 4:00 PM EDT - Market closed

Company Description

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.

Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.

The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Intensity Therapeutics, Inc.
Intensity Therapeutics logo
Country United States
Founded 2012
IPO Date Jun 30, 2023
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Lewis Bender

Contact Details

Address:
1 Enterprise Drive, Suite 430
Shelton, Connecticut 06484-4779
United States
Phone 203 221 7381
Website intensitytherapeutics.com

Stock Details

Ticker Symbol INTS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001567264
CUSIP Number 45812M104
ISIN Number US45828J1034
Employer ID 46-1488089
SIC Code 2836

Key Executives

Name Position
Lewis H. Bender M.A., M.B.A., M.S. Founder, President, Chief Executive Officer and Chairman of the Board
Joseph Talamo CPA, M.B.A. Chief Financial Officer
John Wesolowski CPA, M.B.A. Principal Accounting Officer and Controller
James M. Ahlers Executive Vice President of Corporate Finance
Brian Schwartz M.D. Executive Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Apr 25, 2025 8-K Current Report
Apr 25, 2025 424B4 Prospectus
Apr 24, 2025 EFFECT Notice of Effectiveness
Apr 24, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 23, 2025 8-K Current Report
Apr 23, 2025 FWP Free Writing Prospectus
Apr 22, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Mar 28, 2025 DRS [Cover] Draft Registration Statement
Mar 13, 2025 8-K Current Report
Mar 13, 2025 10-K Annual Report